KDR and neoplasm: Anlotinib is a new oral multi-target tyrosine kinase inhibitor (TKI) that can effectively inhibit vascular endothelial growth factor receptors (VEGFR), and is used for the treatment of advanced NSCLC.9 Anti-angiogenic drugs can normalize blood vessels, improve the tumor microenvironment, and promote immune cells and lymphocytes to enter tumor tissues more easily.